Hayes D F
Breast Cancer Center Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Recent Results Cancer Res. 1998;152:71-85. doi: 10.1007/978-3-642-45769-2_7.
TMUGS should help make order out of the chaos that exists in evaluation of tumor markers for clinical use. Although it seems cumbersome at first, application of this system by expert reviewers should help separate those markers for which clinical utility clearly exists from those markers for which either more data are necessary or for which further consideration can be discarded. Perhaps as important, this system may serve as a framework in which clinical and translational investigators can design studies prospectively to generate LOE I or II data, and thus hasten the acceptance of new biologic factors into routine clinical practice.
TMUGS应有助于理清临床应用中肿瘤标志物评估的混乱局面。尽管一开始这似乎很繁琐,但专家评审员应用该系统应有助于将那些临床效用明确的标志物与那些需要更多数据或可摒弃进一步考虑的标志物区分开来。也许同样重要的是,该系统可作为一个框架,临床和转化研究人员可以在此框架内前瞻性地设计研究,以生成I级或II级证据数据,从而加速新生物因子被纳入常规临床实践。